Saturday, 10 April 2021, 5:01 pm
Should not a medicine (Remdesivir) that has shown
lifesaving effect in certain cases of Covid-19 be made
available to all those who need it without delay? Even if
Big Pharma has a patent, there are provisions in the global
trade treaties that allow governments to issue compulsory
licenses to such a lifesaving drug, and keep people over
profit. This is why medical experts are demanding
governments to use compulsory licensing for generic
production of such a drug to help save
lives.
Compulsory licensing is one of the key public
health and social justice safeguards that allows governments
Experts demand compulsory licensing for generic production of a drug against COVID-19
modernghana.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernghana.com Daily Mail and Mail on Sunday newspapers.
Prices of medicines to go up a tad; companies seek 20% jump | India News
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
To print this article, all you need is to be registered or login on Mondaq.com.
Historically pharmaceutical companies turned to contract
manufacturers for achieving efficiencies in cost, capacity and
time-to-market, or to obtain specific expertise not available
in-house. However, the increment in outsourcing of manufacture is
driven, at least in part, by the fact that contract manufacturers
have increasingly developed innovative proprietary processes and
implemented technology that may well surpass that available at the
pharmaceutical client s own facilities. Moreover, nowadays few
pharmaceuticals are made in dedicated plants and key intermediates
and active compounds can be made in general-purpose plants.